Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Inspiratory Muscle Training on Postural Stability, Balance, Pulmonary Function and Functional Capacity in Children With Cystic Fibrosis
Brief Summary: It is extensively reported in the literature that patients with chronic obstructive lung disease may have impairments in balance and postural control which further increase the disease burden. Mechanisms related to these impairments include, but are not limited to increased work of breathing, diaphragm weakness, peripheral muscle weakness and systemic inflammation. Since the similar symptoms are reported for the children with cystic fibrosis, it is hypothesized that balance and postural control may also be compromised in these patients. Inspiratory muscle training (IMT) is shown to improve diaphragm strength and pulmonary function. Considering the relation between diaphragm which is one of the core muscles, and balance, IMT may also have an impact on postural control and balance alongside the standard clinical parameters such as respiratory muscle strength, pulmonary function and functional capacity in these patients. Thus, the aim of this study was to investigate the effects of inspiratory muscle training and conventional chest physiotherapy on postural stability, balance, pulmonary function and functional capacity in children with cystic fibrosis.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: LUM 600 mg qd/IVA 250 mg q12h; Type: EXPERIMENTAL; Interventions: Drug: Lumacaftor Plus Ivacaftor Combination, Drug: Ivacaftor | Arm Label: LUM 400 mg q12h/ IVA 250 mg q12h; Type: EXPERIMENTAL; Interventions: Drug: Lumacaftor Plus Ivacaftor Combination | Intervention Type: DRUG; Name: Lumacaftor Plus Ivacaftor Combination; Assigned to Arm(s): LUM 400 mg q12h/ IVA 250 mg q12h, LUM 600 mg qd/IVA 250 mg q12h | Intervention Type: DRUG; Name: Ivacaftor; Assigned to Arm(s): LUM 600 mg qd/IVA 250 mg q12h | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Cycling in combination with Flutter® therapy; Type: EXPERIMENTAL; Interventions: Device: Flutter® | Arm Label: Cycling without Flutter® therapy; Type: ACTIVE_COMPARATOR; Interventions: Device: No Flutter® | Intervention Type: DEVICE; Name: Flutter®; Assigned to Arm(s): Cycling in combination with Flutter® therapy | Intervention Type: DEVICE; Name: No Flutter®; Assigned to Arm(s): Cycling without Flutter® therapy
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: LUM/IVA; Type: EXPERIMENTAL; Interventions: Drug: LUM/IVA | Intervention Type: DRUG; Name: LUM/IVA; Assigned to Arm(s): LUM/IVA | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Other: Conventional chest physiotherapy | Arm Label: Training Group; Type: EXPERIMENTAL; Interventions: Other: Conventional chest physiotherapy, Other: Inspiratory muscle training | Intervention Type: OTHER; Name: Conventional chest physiotherapy; Assigned to Arm(s): Control Group, Training Group | Intervention Type: OTHER; Name: Inspiratory muscle training; Assigned to Arm(s): Training Group

Answer: D